A 28-year-old man with HIV infection (CD4 count 80 cells/μL) presents with painful vesicles on the genitals and perianal region for 5 days. The lesions are small, grouped on an erythematous base, and have begun to ulcerate. He reports a history of similar lesions 6 months ago. Direct fluorescent antibody (DFA) testing confirms HSV-2. He is currently on antiretroviral therapy but not on antiviral prophylaxis. What is the most appropriate initial management?

Explanation

## Management of HSV-2 in Advanced HIV ### Clinical Context This patient has: - **Recurrent HSV-2 infection** (history 6 months prior) - **Severe immunosuppression** (CD4 <100 cells/μL) - **Confirmed HSV-2 by DFA** - **Genital/perianal ulcerative lesions** ### Treatment Algorithm ```mermaid flowchart TD A[HSV-2 infection in HIV patient]:::outcome --> B{CD4 count and severity?}:::decision B -->|CD4 > 200, mild-moderate| C[Oral acyclovir 400 mg 5x daily]:::action B -->|CD4 < 50, severe/disseminated| D[IV acyclovir 5 mg/kg q8h]:::action B -->|Localized, CD4 50-200| E[Oral acyclovir 400-800 mg 5x daily]:::action C --> F[7-10 days for primary; 5-7 days for recurrent]:::action E --> F D --> G[7-10 days; consider switch to oral when improving]:::action F --> H[Immune reconstitution with ART]:::outcome G --> H ``` ### Rationale for Oral Acyclovir 400 mg Five Times Daily **Key Point:** For recurrent HSV-2 in a patient with CD4 <200 cells/μL, **oral acyclovir 400 mg five times daily for 7–10 days** is the standard first-line therapy, provided the patient can tolerate oral intake and there is no evidence of disseminated or severe disease. **High-Yield:** The choice between oral and IV depends on: | Factor | Oral Acyclovir | IV Acyclovir | |--------|----------------|---------------| | **CD4 threshold** | Generally adequate if CD4 > 50 cells/μL | Preferred if CD4 < 50 or severe/disseminated | | **Bioavailability** | ~15–20% (adequate for mucocutaneous HSV) | 100% (needed for CNS or systemic disease) | | **Indication** | Localized genital/perianal lesions | Encephalitis, disseminated, severe immunosuppression | | **Duration** | 7–10 days (recurrent) or 10 days (primary) | 7–10 days, then switch to oral | ### Clinical Pearl **Clinical Pearl:** Although this patient's CD4 is <100 cells/μL, the lesions are **localized to genital/perianal skin** (not disseminated or CNS involvement). Oral acyclovir achieves sufficient concentrations in skin and genital tissues to treat mucocutaneous HSV-2 effectively. IV acyclovir is reserved for: - Disseminated HSV (esophagitis, hepatitis, pneumonitis) - HSV encephalitis or meningitis - Severe immunosuppression (CD4 <50) with inability to take oral medication or poor response to oral therapy ### Secondary Prophylaxis **High-Yield:** After the acute episode resolves, this patient should receive **secondary prophylaxis** with oral acyclovir 400 mg twice daily (or valacyclovir 500 mg daily) to prevent recurrence, given the history of recurrent HSV-2 and CD4 <100. Prophylaxis can be discontinued once CD4 >200 cells/μL for >3 months on ART. ### Why Not Topical Therapy? Topical acyclovir is **insufficient** for systemic or recurrent HSV infection, especially in advanced HIV. It is reserved for localized, non-recurrent lesions in immunocompetent patients and provides poor bioavailability for deep tissue penetration. [cite:Harrison 21e Ch 187; CDC/NIH Opportunistic Infections Guidelines]